| 生物活性 | |||
|---|---|---|---|
| 靶点 | 
 | ||
| 描述 | Nampt inhibition by (E)-Daporinad (FK866) leads to a significant reduction in NAD+ levels intracellularly, selectively killing multiple myeloma (MM) cells. The cell death induced by (E)-Daporinad is linked to the inhibition of Nampt activity, not its protein expression. MM cells, having higher baseline NAD+ levels compared to normal peripheral blood mononuclear cells (PBMCs), are more susceptible to (E)-Daporinad. Additionally, (E)-Daporinad neutralizes the survival benefits that the bone marrow microenvironment confers on MM cells[1]. (E)-Daporinad (FK866) inhibits the increase in intracellular calcium ([Ca2+].i) that is typically induced by various mitogens and decreases the calcium content of thapsigargin-responsive calcium stores in Jurkat cells and activated peripheral blood lymphocytes (PBLs). However, it does not affect the calcium content in Bcl2-overexpressing Jurkat cells[2]. The inhibition of NAMPT by (E)-Daporinad (FK866), or SIRT by nicotinamide, reduces cell proliferation and induces cell death in 293T cells. This effect involves the p53 acetylation pathway, highlighting a critical regulatory mechanism in cell survival and death[3]. | ||
| 细胞研究 | |||||
|---|---|---|---|---|---|
| 细胞系 | 浓度 | 检测类型 | 检测时间 | 活性说明 | 数据源 | 
| human A2780 cells | Proliferation assay | 72 h | Antiproliferative activity against human A2780 cells after 72 hrs by sulforhodamine B assay, IC50=1 nM | 24405419 | |
| human A431 cells | Cytotoxic assay | Cytotoxicity against human A431 cells by clonogenic assay, IC50=6.1 nM | 24164086 | ||
| human A549 cells | Cytotoxic assay | 6 days | Cytotoxicity against human A549 cells after 6 days by SRB assay, IC50=0.16 μM | 21330015 | |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
| 1 mM 5 mM 10 mM | 2.55mL 0.51mL 0.26mL | 12.77mL 2.55mL 1.28mL | 25.54mL 5.11mL 2.55mL | 
| 参考文献 | 
|---|